All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Abrocitinib
Therapeutic Area: Dermatology Product Name: PF-04965842
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
Patients were randomized into one of three arms: 200mg, 100mg, or placebo. Both doses of abrocitinib met the primary endpoint, resulting in significantly fewer patients experiencing flaring, compared to those randomized to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Abrocitinib
Therapeutic Area: Dermatology Product Name: PF-04965842
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
Details:
Filings based on robust abrocitinib clinical trial data demonstrating significant symptom improvement versus placebo as well as a consistent safety profile.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Abrocitinib
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
Results showed that the percentage of patients achieving each co-primary efficacy endpoint at Week 12 was statistically significantly higher with both doses of abrocitinib than with placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Abrocitinib
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
Abrocitinib met all key endpoints,demonstrating statistically superior improvements in skin clearance, disease extent and severity, and itch compared to placebo.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Abrocitinib
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020
Details:
JADE COMPARE trial met all co-primary endpoints Study included dupilumab in active control arm Safety profile for abrocitinib consistent with previous studies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Upadacitinib
Therapeutic Area: Dermatology Product Name: Rinvoq
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
New RINVOQ analyses from the Measure Up 1 and 2 monotherapy studies show improvements in additional measures of skin clearance, itch and quality of life in adult and adolescent patients with moderate to severe atopic dermatitis.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
